Performance of STOK Stoke Therapeutics | -1.5% in 12m
Compare STOK with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Stoke Therapeutics with its related Sector/Index XBI
Performance Duell STOK vs XBI
| TimeFrame | STOK | XBI |
|---|---|---|
| 1 Day | -4.41% | -0.94% |
| 1 Week | -4.49% | -2.04% |
| 1 Month | -10.0% | -2.01% |
| 3 Months | 145.8% | -3.19% |
| 6 Months | 169.5% | 31.67% |
| 12 Months | -1.46% | 1.00% |
| YTD | 95.9% | -2.32% |
| Rel. Perf. 1m | -0.94 | |
| Rel. Perf. 3m | 7.98 | |
| Rel. Perf. 6m | 7.01 | |
| Rel. Perf. 12m | -0.35 |
Is Stoke Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Stoke Therapeutics (NASDAQ:STOK) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -74.11 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of STOK as of May 2024 is 12.43. This means that STOK is currently overvalued and has a potential downside of 8.28% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of STOK as of May 2024 is 12.43. This means that STOK is currently overvalued and has a potential downside of 8.28% (Sold with Premium).
Is STOK a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: STOK is performing better - Values below 0%: STOK is underperforming
Compare STOK with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -6.36% | -11.34% | 150.42% | -29.44% |
| US NASDAQ 100 | QQQ | -6.00% | -10.87% | 152.20% | -38.33% |
| US Dow Jones Industrial 30 | DIA | -6.66% | -12.86% | 153.19% | -21.53% |
| German DAX 40 | DBXD | -8.57% | -13.47% | 146.69% | -18.96% |
| UK FTSE 100 | ISFU | -7.07% | -16.20% | 149.88% | -13.78% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -3.66% | -15.61% | 166.26% | 9.28% |
| Hongkong Hang Seng | HSI | -7.51% | -21.78% | 164.22% | 9.19% |
| Japan Nikkei 225 | EXX7 | -2.75% | -5.36% | 156.65% | -17.19% |
| India NIFTY 50 | INDA | -1.91% | -8.40% | 154.02% | -24.85% |
| Brasil Bovespa | EWZ | -2.32% | -8.56% | 168.46% | -15.74% |
STOK Stoke Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -6.46% | -9.81% | 149.41% | -41.21% |
| Consumer Discretionary | XLY | -4.60% | -9.76% | 158.69% | -22.41% |
| Consumer Staples | XLP | -6.78% | -14.48% | 155.23% | -5.77% |
| Energy | XLE | -5.85% | -5.98% | 154.99% | -23.80% |
| Financial | XLF | -7.65% | -12.33% | 145.05% | -34.18% |
| Health Care | XLV | -6.45% | -11.44% | 154.84% | -11.38% |
| Industrial | XLI | -6.86% | -11.31% | 145.87% | -30.53% |
| Materials | XLB | -7.07% | -10.28% | 149.50% | -20.51% |
| Real Estate | XLRE | -6.62% | -10.62% | 157.61% | -6.14% |
| Technology | XLK | -5.97% | -10.44% | 154.54% | -37.94% |
| Utilities | XLU | -8.67% | -19.98% | 149.23% | -7.75% |
| Aerospace & Defense | XAR | -6.43% | -15.31% | 151.47% | -27.25% |
| Biotech | XBI | -2.45% | -8.02% | 137.81% | -2.46% |
| Homebuilder | XHB | -6.67% | -13.03% | 130.30% | -53.76% |
| Retail | XRT | -5.80% | -11.42% | 144.36% | -24.47% |
Does Stoke Therapeutics outperform its market, is STOK a Sector Leader?
No, over the last 12 months Stoke Therapeutics (STOK) made -1.46%, while its related Sector, the SPDR S&P Biotech (XBI) made 1.00%.
Over the last 3 months STOK made 145.82%, while XBI made -3.19%.
No, over the last 12 months Stoke Therapeutics (STOK) made -1.46%, while its related Sector, the SPDR S&P Biotech (XBI) made 1.00%.
Over the last 3 months STOK made 145.82%, while XBI made -3.19%.
| Period | STOK | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -10.03% | -2.01% | 1.31% |
| 3 Months | 145.82% | -3.19% | 4.24% |
| 12 Months | -1.46% | 1.00% | 27.98% |